Why BGPT?
logo

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.

Press Enter ↵ to search evidence


     Quick Explanation



    I can’t evaluate “Neeru Singh biomarkers” as “best evidence” yet because no specific biomarker names, diseases, cohorts, assay methods, effect sizes, or papers/DOIs were provided.


     Long Explanation



    Evidence-battle-test request: what’s missing
    “Best Evidence: Neeru Singh biomarkers” is currently not evaluable in a scientific, citation-grounded way because the prompt does not include any of the concrete items needed to verify biomarker validity (e.g., biomarker list, target condition, study design, cohort size, assay, performance metrics, and the actual primary sources).
    What you can paste to unlock a rigorous critique (minimal)
    • Disease/phenotype (e.g., diagnosis/prognosis; exact wording)
    • Biomarker names (protein/metabolite/cytokine/gene signature; exact analytes)
    • Assay type (ELISA, mass spec, qPCR, panel, etc.)
    • Primary study citation(s) (PMID/DOI/URL or full author+year)
    • Reported metrics (AUC/SE, sensitivity/specificity at a threshold, CI, normalization)
    • Validation status (internal vs external cohort; blinded? pre-registered?)
    How I will critique “best evidence” once you provide sources
    1. Source authenticity: confirm exact primary endpoints and which dataset(s) were used.
    2. Performance quality: evaluate discrimination vs calibration (if available), overfitting risk, and whether performance survives independent cohorts.
    3. Biological plausibility (without overclaiming): check whether markers map to known pathways relevant to the stated condition—only if supported by cited data.
    4. Bias audit: look for confounding, batch effects, selection bias, and selective reporting (requires methods + supplementary tables).
    5. Threats to validity: reproducibility, measurement drift, cohort heterogeneity, and metric fragility across thresholds.
    Next action
    Click the agent button to fetch and analyze the primary “Neeru Singh biomarkers” evidence set once identifiers/papers are available in BGPT’s indexed sources.


    Feedback:    

    Updated: March 26, 2026

     Analysis Wizard



    Not executed because the required primary sources (biomarker list, endpoints, DOI/PMID) are not provided.



     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT